T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

NCT01967823 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

11

Enrollment

NIH

Sponsor class

Conditions

Melanoma
Meningioma
Breast Cancer
Non-Small Cell Lung Cancer
Hepatocellular Cancer

Interventions

BIOLOGICAL: Anti-NY ESO-1 mTCR PBL
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Aldesleukin

Sponsor

National Cancer Institute (NCI)